SMAD1 Loss-of-Function Variant Responsible for Congenital Heart Disease

Wang, Zhi; Qiao, Xiao-Hui; Xu, Ying-Jia; Liu, Xing-Yuan; Huang, Ri-Tai; Xue, Song; Qiu, Hai-Yan; Yang, Yi-Qing

doi:https://doi.org/10.1155/2022/9916325

BioMed Research International

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusions Data Availability Conflicts of Interest Authors’ Contributions Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2022 | Article ID 9916325 | https://doi.org/10.1155/2022/9916325

SMAD1 Loss-of-Function Variant Responsible for Congenital Heart Disease

Zhi Wang,¹Xiao-Hui Qiao,¹Ying-Jia Xu,²Xing-Yuan Liu,³Ri-Tai Huang,⁴Song Xue,⁴Hai-Yan Qiu,¹and Yi-Qing Yang^2,5,6

Academic Editor: Syed Sameer Aga

Received13 Dec 2021

Accepted16 Feb 2022

Published03 Mar 2022

Abstract

As the most common form of developmental malformation affecting the heart and endothoracic great vessels, congenital heart disease (CHD) confers substantial morbidity and mortality as well as socioeconomic burden on humans globally. Aggregating convincing evidence highlights the genetic origin of CHD, and damaging variations in over 100 genes have been implicated with CHD. Nevertheless, the genetic basis underpinning CHD remains largely elusive. In this study, via whole-exosome sequencing analysis of a four-generation family inflicted with autosomal-dominant CHD, a heterozygous SMAD1 variation, NM_005900.3: c.264C > A; p.(Tyr88), was detected and validated by Sanger sequencing analysis to be in cosegregation with CHD in the whole family. The truncating variation was not observed in 362 unrelated healthy volunteers employed as control persons. Dual-luciferase reporter gene assay in cultured COS7 cells demonstrated that Tyr88-mutant SMAD1 failed to transactivate the genes TBX20 and NKX2.5, two already well-established CHD-causative genes. Additionally, the variation nullified the synergistic transcriptional activation between SMAD1 and MYOCD, another recognized CHD-causative gene. These data indicate SMAD1 as a new gene responsible for CHD, which provides new insight into the genetic mechanism underlying CHD, suggesting certain significance for genetic risk assessment and precise antenatal prevention of the family members inflicted with CHD.

1. Introduction

Congenital heart disease (CHD) constitutes the most frequent type of birth deformity in humans, inflicting ~1% of live births globally [1, 2]. Based on cardiac anatomic abnormalities, CHD is clinically categorized into >20 distinct types, including pulmonary stenosis (PS), ventricular septal defect (VSD), atrial septal defect, patent ductus arteriosus (PDA), and tetralogy of Fallot [1]. CHD may result in neurodevelopmental abnormality, thromboembolic complications, infective endocarditis, pulmonary hypertension, heart failure, arrhythmias, and death [3, 4]. Tremendous advancement has been achieved in pediatric cardiovascular surgery during recent decades, which enables the overwhelming majority (up to 97%) of neonates with CHD to survive childhood and reach adulthood, and now, CHD adults outnumber CHD children [5, 6]. Unfortunately, prolonged life span has led to an increasing number of adult CHD survivors, who are prone to suffering from miscellaneous late complications, with heart failure and cardiac arrhythmias being the most prominent [7, 8]. Consequently, CHD has conferred substantial morbidity and mortality as well as socioeconomic burden on humans [1]. Despite clinical importance, the etiologies accountable for CHD remain largely obscure.

It has been demonstrated that cardiac morphogenesis is a sophisticated biological process and both genetic defects and nongenetic precipitating risk factors may disturb this complex process, giving rise to CHD [2, 9–14]. Well-documented nongenetic risk factors predisposing to CHD include maternal diabetes, folate deficiency, viral infections, autoimmune disorder, and environmental exposures to air pollutants and medications [9]. However, aggregating evidence indicates that genetic components exert a key effect on the occurrence of CHD, and in addition to chromosomal alterations (aneuploidies) and copy number variations, pathogenic mutations in >100 genes, including TBX20, NKX2.5, and MYOCD, have been involved in the occurrence of CHD [2, 10–14]. Nevertheless, the genetic culprit components for CHD in up to 55% of cases remain unveiled [12]. Hence, there is still much research work to be fulfilled to show a complete picture of genetic causes for CHD.

2. Materials and Methods

2.1. Recruitment of Research Participants

The current research was completed in conformity with the guidelines of the World Medical Association Declaration of Helsinki. Approval of the research protocol was achieved from the local institutional medical ethics committee, with an ethical approval number of LL(H)-09-07. Written informed consent was provided by the study participants or their parents. For this research, a four-generation pedigree with high incidence of autosomal-dominant CHD was enlisted. A total of 362 unrelated ethnicity-matched volunteers without CHD were recruited as control individuals. All research participants experienced a comprehensive clinical investigation, encompassing review of personal and medical histories as well as familial histories, careful physical examination, transthoracic echocardiogram, and electrocardiogram. Diagnosis of CHD was made as previously described [15]. Peripheral blood specimen was collected from each study subject, and genomic DNA was prepared from blood leucocytes of each study subject.

2.2. Molecular Genetic Studies

For a study participant, a whole-exome library was prepared using 2 μg of genomic DNA and captured with the SureSelect Human All Exon V6 Kit (Agilent Technologies), as per the manufacturer’s manual. The exome library was enriched and then sequenced on the Illumina HiSeq 2000 Genome Analyzer (Illumina) using the HiSeq Sequencing Kit (Illumina), following the protocol. Bioinformatics assays of the data produced by whole-exome sequencing (WES) were performed as previously described [16–19]. The candidate variants identified by WES and bioinformatical analyses of the DNA samples from the CHD family underwent Sanger sequencing analysis in the whole family with CHD. For a verified genetic variation, the entire coding region and splicing donors/acceptors of the gene were sequenced in all available family members of the family with CHD and 362 unrelated control persons and such population genetics database as the Single Nucleotide Polymorphism (SNP) Database (https://www.ncbi.nlm.nih.gov/) and the Genome Aggregation Database (gnomAD; https://gnomad.broadinstitute.org/) were consulted to check its novelty.

2.3. Generation of Eukaryotic Gene Expression Plasmids

Preparation of cDNAs from discarded human heart samples was described elsewhere [4]. The full-length cDNA of wild-type human SMAD1 (accession no. NM_005900.3) was amplified on a thermocycler (Applied Biosystems) by polymerase chain reaction (PCR) utilizing high-fidelity DNA polymerase (Stratagene) with a specific pair of primers (forward: 5-GACGCTAGCCCAAGGAGTATAACTAGTGC-3; backward: 5-GTCCTCGAGGTCTGACTCATCCATCCTTC-3). The produced SMAD1 cDNAs and the pcDNA3.1 plasmid DNAs were doubly digested by NheI (NEB) and XhoI (NEB), respectively and then purified with a gel extraction kit (Qiagen), and finally, the purified SMAD1 cDNA was inserted into the pcDNA3.1 plasmid at the NheI-XhoI sites to create a recombinant SMAD1-pcDNA3.1 expression plasmid. The identified genetic variation was introduced into wild-type SMAD1-pcDNA3.1 via site-directed mutagenesis using a site-directed mutagenesis kit (Stratagene) and a complementary pair of primers (forward: 5-GCCTCATGTCATTTAATGCCGTGTGTGGCGC-3; backward: 5-GCGCCACACACGGCATTAAATGACATGAGGC-3) and was validated by Sanger sequencing. Likewise, the full-length cDNA of wild-type human MYOCD (accession no. NM_001146312.3) was amplified by PCR, doubly digested with NheI (NEB) and XhoI (NEB), and subcloned into pcDNA3.1 (doubly digested with NheI and XhoI) at the NheI-XhoI sites to create the eukaryotic expression plasmid MYOCD-pcDNA3.1. A 980 bp fragment (from –980 to –1) of human TBX20 (accession no. NC_000007.14) was amplified by PCR from human genomic DNA utilizing high-fidelity DNA polymerase (Stratagene) and a specific pair of primers (forward: 5-GTTGCTAGCGTCAGCCTGAGTTTACACGG-3; backward: 5-AACCTCGAGCCTGGCGCTCGCTGCCCTGC-3), cut with NheI (NEB) and XhoI (NEB), and inserted into the promoter-less pGL3-basic vector (Promega), which was cut with NheI (NEB) and XhoI (NEB), to generate a TBX20 promoter-driven firefly luciferase reporter vector (TBX20-luc). Similar with a previous report [20], a human NKX2.5 promoter-driven firefly luciferase reporter vector (NKX2.5-luc) was constructed. Each construct was confirmed by Sanger sequencing analysis.

2.4. Cellular Transient Transfection and Reporter Gene Analysis

COS7 cells were maintained in Dulbecco’s modified Eagle’s medium (Thermo Fisher Scientific) with 10% fetal bovine serum (Gibco), 100 IU/mL penicillin (Sigma-Aldrich,), and 100 μg/mL streptomycin (Sigma-Aldrich), in a cell culture incubator at 37°C with an atmosphere of 95% air as well as 5% CO₂. Cells were cultured in a 12-well plate 24 h before transient transfection. Cells were transiently transfected with expression plasmids by employing the ViaFect™ Transfection Reagent (Promega). The plasmid pGL4.75 (Promega), which expresses Renilla luciferase, was cotransfected as an internal control to balance transfection efficiency, and the total amount of various plasmid DNAs per well was kept constant by supplementing the empty plasmid pcDNA3.1 where necessary. Unless otherwise indicated, 1000 ng of firefly luciferase reporter plasmid (TBX20-luc or NKX2.5-luc), 20 ng of Renilla luciferase control plasmid (pGL4.75), and 200 ng of each activator expression plasmid (wild-type SMAD1-pcDNA3.1, Tyr88-mutant SMAD1-pcDNA3.1 or MYOCD-pcDNA3.1, singly or in combination) were used. The luciferase activities were analyzed as described previously [21], with a dual-luciferase analysis system (Promega).

2.5. Statistical Analysis

The activity of a promoter was given as a ratio of firefly luciferase to Renilla luciferase. Values for promoter activity were expressed as deviation (SD) of the results from three transfection experiments in triplicate. Student’s -test was applied to statistical analysis. A two-sided denoted statistical difference.

3. Results

3.1. Clinical Characteristic Information of the Study Pedigree

In the present investigation, a large family with CHD spanning four generations (Figure 1(a)) was enrolled from the Chinese Han-race population. In this Chinese family, there were 32 family members, including 30 living members (15 male members and 15 female members, with ages ranging from 3 to 55 years) and all the nine affected members had echocardiogram-documented PDA. In addition, four members also suffered from VSD and three members also suffered from PS. Genetic analysis of this four-generation pedigree (Figure 1(a)) revealed that PDA was inherited in an autosomal-dominant fashion, with 100% penetrance. The proband, a three-year-old boy, underwent catheter-based cardiac repairment due to PDA and VSD. The proband’s affected relatives also underwent interventional procedures for correction of CHD, except for his mother’s grandfather (I-1), who died of congestive heart failure at the age of 69 years. No recognized noninherited risk factors contributing to CHD were ascertained in all the family members. The basic clinical information of the affected family members with CHD is provided in Table 1.

(a)

(b)

(c)

Figure 1

Novel SMAD1 mutation underpinning familial congenital cardiac deformity. (a) Pedigree suffering from congenital heart deformities. Pedigree members are identified by generations and numbers. “⁺” Represents a carrier of the heterogeneous SMAD1 variation; “^–” means a noncarrier. (b) Sequence chromatogram traces illustrating the SMAD1 variation (in heterozygous status) from the index patient (mutant) and its wild-type control (in homozygous status) from a healthy family member (wild type). A rectangle symbol marks a genetic codon, with an arrow directing the nucleotide site where the mutation occurred. (c) Schemas describing the functional domains of SMAD1. NH2: amino-terminus; MAD: mothers against decapentaplegic; COOH: carboxyl-terminus.

3.2. Detection of a CHD-Causing SMAD1 Mutation

WES was carried out in four CHD-inflicted family members (including III-5, III-12, IV-4, and IV-7) and three unaffected family members (including III-6, III-11, and IV-3) of the family (Figure 1(a)), yielding approximately 22 Gb of sequence data for each study family member, with ~98% locating to the human genome (hg19) and~75% mapping to the target sequences. A mean of 16,206 exonic variants (ranging from 15,382 to 17,098) per study family member that passed filtering by the inheritance model, of which 11 heterozygous nonsense and missense variants passed filtering by ANNOVAR, was carried by the four CHD-inflicted family members and was predicted to be disease causing, with a minor allele , as shown in Table 2. Further genetic assays unveiled that only the variant chr4:146,436,029C > A (GRCh37: NC_000004.11), equivalent to chr4:145,514,877C > A (GRCh38: NC_000004.12) or NM_005900.3: c.264C > A; p.(Tyr88), in SMAD1, was verified by Sanger sequencing with the primer pairs given in Table 3 and was shown to be in cosegregation with CHD in the entire family. The electropherogram traces illustrating the SMAD1 variation in the heterozygous status as well as its wild-type control base are presented in Figure 1(b). The schemas exhibiting the key functional domains of wild-type SMAD1 and Tyr88-mutant SMAD1 are exhibited in Figure 1(c). The identified SMAD1 variant was neither observed in 724 control chromosomes nor reported in the databases of SNP and gnomAD, suggesting a novel SMAD1 variant. This SMAD1 variant, NM_005900.3: c.264C > A; p.(Tyr88), was submitted to Leiden Open Variation Database (LOVD; https://databases.lovd.nl/shared/genes/SMAD1), with a variant number of 0000838399 (https://databases.lovd.nl/shared/variants/0000838399#00019404) and an individual identity number of 00401998 (https://databases.lovd.nl/shared/individuals/00401998).

3.3. Functional Loss of Tyr88-Mutant SMAD1

As shown in Figure 2, wild-type SMAD1 and Tyr88-mutant SMAD1 transactivated the promoter of TBX20 by ~9-fold and ~1-fold, respectively (wild-type SMAD1 versus Tyr88-mutant SMAD1: ; ). When wild-type SMAD1 and Tyr88-mutant SMAD1 was cotransfected, the induced transcriptional activity was ~4-fold (wild-type SMAD1 + empty plasmid pcDNA3.1 versus wild-type SMAD1 + Tyr88-mutant SMAD1: ; ).

Figure 2

Functional impairment of SMAD1 caused by the variation. Dual-luciferase reporter analysis of the transcriptional activation of TBX20 promoter-driven firefly luciferase in cultured COS7 cells by equal amount of wild-type or Tyr88-mutant SMAD1 plasmid, singly or in combination, demonstrated that Tyr88-mutant SMAD1 lost transcriptional activity. Three transient transfection experiments were performed in triplicate for every expression plasmid. The results are reported as the deviation of the data from three independent reporter assays. and , when compared with wild-type SMAD1 (400 ng).

3.4. Nullified Synergistic Transcriptional Activation Between SMAD1 and MYCOD by the Tyr88 Mutation

As shown in Figure 3, wild-type SMAD1 and Tyr88-mutant SMAD1 transactivated the promoter of NKX2.5 by ~4-fold and ~1-fold, respectively (wild-type SMAD1 versus Tyr88-mutant SMAD1: ; ). In the presence of wild-type MYCOD, wild-type SMAD1 and Tyr88-mutant SMAD1 transcriptionally activated the promoter of NKX2.5 by ~29-fold and ~11-fold, respectively (wild-type SMAD1 + wild-type MYCOD versus Tyr88-mutant SMAD1 + wild-type MYCOD: ; ).

Figure 3

Nullified synergistic transactivation between SMAD1 and MYOCD by the variation. Biological measurements of the synergistic transcriptional activation of the NKX2.5 promoter in cultivated COS7 cells by SMAD1; MYOCD was abrogated by the Tyr88 variation. Three cellular transfection experiments were repeated in triplicate for every expression plasmid. All values are given as the deviation of the results from three independent reporter gene analyses. Both and indicate that , in comparison with their corresponding wild-type counterparts.

4. Discussion

In the present study, a four-generation Chinese family suffering from CHD transmitted as an autosomal dominant trait was enrolled. Via WES analysis of the DNA samples from the family members, a novel variation in the SMAD1 gene, NM_005900.3: c.264C > A; p.(Tyr88), was identified, which was confirmed by Sanger sequencing analysis to be in cosegregation with CHD in the whole family. The heterozygous variation was absent from 724 control chromosomes nor reported in the databases of SNP and gnomAD. Reporter gene assays demonstrated that Tyr88-mutant SMAD1 failed to transcriptionally activate the promoters of TBX20 and NKX2.5, two well-established CHD-causing genes [22, 23]. Moreover, the mutation nullified the synergistic transcriptional activation between SMAD1 and MYOCD, another CHD-causative gene [11, 24–26]. These observational results indicate that genetically compromised SMAD1 predisposes to CHD.

SMAD1 maps on human chromosome 4q31.21, coding for a protein comprising 465 amino acids, a member of the SMAD superfamily of proteins like the products of the Sma gene from Caenorhabditis elegans and the Mad (Mothers against decapentaplegic) gene from Drosophila [27, 28]. As a transcription factor and signal transducer that regulates multiple signal pathways, the SMAD1 protein possesses two evolutionarily conserved structural domains, MAD homology 1 (MH1) and MAD homology 2 (MH2), which are separated by Linker [29]. MH1 functions mainly to bind to the DNA consensus sequence of GNCN in target gene promoters and to transcriptionally activate the expression of target genes, in addition to mediating nuclear accumulation of SMAD1 and interaction of SMAD1 with other transcription factors. MH2 is responsible for the interaction of SMAD1 with a wide variety of proteins, provides selectivity and specificity to SMAD1 function, contributes to the binding affinity, and is involved in nuclear accumulation of SMAD1. Linker connecting MH1 and MH2 contains multiple critical peptide motifs, encompassing a nuclear export signal and several potential phosphorylation sites, and hence has a role in transcriptional activation [29]. SMAD1 is highly expressed in the heart throughout embryogenesis, playing a crucial role in transactivating the expression of target genes essential for cardiovascular morphogenesis, including TBX20, NKX2.5, ACTC1, and MYH6, alone or synergistically with MYOCD and TBX20 [30–32]. Furthermore, loss-of-function variations in TBX20, NKX2.5, ACTC1, MYH6, and MYOCD have been involved in the molecular pathogenesis of CHD [11, 22, 23, 33–36]. In the current study, the variation discovered in cases with familial CHD was predicted to generate a truncating SMAD1 protein lacking MH2 and Linker as well as a part of MH1 and functional data demonstrated that Tyr88-mutant SMAD1 failed to transactivate its downstream target genes. These findings support that haploinsufficiency of SMAD1 is the genetical mechanism of CHD which occurred in this family.

It may be ascribed to abnormal cardiovascular development that SMAD1 mutation gives rise to CHD. In most animal species, including xenopus, zebrafish, mice, rats, and humans, SMAD1 is amply expressed in the cardiovascular system during embryonic development, playing a pivotal role in cardiovascular morphogenesis via mediating the cellular proliferation, growth, apoptosis, differentiation, and morphogenesis in the heart and vessels [29, 37]. In mice, homozygous knockout of Smad1 led to embryonic demise because the embryos failed to seed the placenta and the Smad1-null embryos showed markedly impaired allantois formation and drastically reduced primordial germ cells; while the embryos with heterozygous deletion of Smad1 developed remarkably normally, probably due to functional compensation by Smad5 and Smad8, which shared common expression profiles and functional characteristics with Smad1 [38, 39]. Although the mice with heterozygous knockout of either Smad1 (Smad1) or Smad5 (Smad5) developed properly, the murine embryos with double heterozygous knockout of Smad1 and Smad5 (Smad1/Smad5) died by E10.5 and the double heterozygous embryos (Smad1/Smad5) presented defects of heart looping and laterality [39]. Furthermore, the mice with conditional knockout of the Smad1 gene by disrupting Smad1 either in endothelial cells or in smooth muscle cells displayed increased pulmonary pressure, right ventricular hypertrophy, and thickened pulmonary arterioles [40]. Collectively, these results from experimental animals suggest that genetically compromised SMAD1 predisposes to CHD in human beings.

5. Conclusions

The current investigation indicates SMAD1 as a novel causative gene responsible for CHD, which provides a new potential target for antenatal prophylaxis and personalized treatment of CHD patients.

Data Availability

The data supporting the findings of this investigation are available upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Zhi Wang, Xiao-Hui Qiao, and Ying-Jia Xu contributed equally to the work.

Acknowledgments

This research was funded by the Basic Research Project of Shanghai, China (grant number 20JC1418800), the Experimental Animal Project of Shanghai, China (grant number 201409004400), the Natural Science Foundation of Ningbo, Zhejiang province, China (grant numbers 202003N4230 and 2018A610388), and the Ningbo Clinical Research Center Project for Children’s Health and Diseases, Zhejiang province, China (grant number 2019A21002).

References

S. S. Virani, A. Alonso, H. J. Aparicio et al., “Heart disease and stroke statistics-2021 update: a report from the American Heart Association,” Circulation, vol. 143, no. 8, pp. e254–e743, 2021.
View at: Publisher Site | Google Scholar
L. Martin and D. W. Benson, “Focused strategies for defining the genetic architecture of congenital heart defects,” Genes, vol. 12, no. 6, p. 827, 2021.
View at: Publisher Site | Google Scholar
Y. Zhang, Y. M. Sun, Y. J. Xu et al., “A new TBX5 loss-of-function mutation contributes to congenital heart defect and atrioventricular block,” International Heart Journal, vol. 61, no. 4, pp. 761–768, 2020.
View at: Publisher Site | Google Scholar
L. Zhao, W. F. Jiang, C. X. Yang et al., “SOX17 loss-of-function variation underlying familial congenital heart disease,” European Journal of Medical Genetics, vol. 64, no. 5, article 104211, 2021.
View at: Publisher Site | Google Scholar
J. K. Triedman and J. W. Newburger, “Trends in congenital heart disease,” Circulation, vol. 133, no. 25, pp. 2716–2733, 2016.
View at: Publisher Site | Google Scholar
B. J. Bouma and B. J. Mulder, “Changing landscape of congenital heart disease,” Circulation Research, vol. 120, no. 6, pp. 908–922, 2017.
View at: Publisher Site | Google Scholar
R. G. Williams, “Late causes of death after congenital heart defects:,” Journal of the American College of Cardiology, vol. 68, no. 5, pp. 499–501, 2016.
View at: Publisher Site | Google Scholar
K. Niwa, H. Kaemmerer, and Y. von Kodolitsch, “Current diagnosis and management of late complications in adult congenital heart disease,” Cardiovascular Diagnosis and Therapy, vol. 11, no. 2, pp. 478–480, 2021.
View at: Publisher Site | Google Scholar
J. I. Kalisch-Smith, N. Ved, and D. B. Sparrow, “Environmental risk factors for congenital heart disease,” Cold Spring Harbor Perspectives in Biology, vol. 12, no. 3, article a037234, 2020.
View at: Publisher Site | Google Scholar
A. Saliba, A. C. V. Figueiredo, J. E. Baroneza et al., “Genetica e genomica na cardiopatia congenita: uma revisao clinica,” Journal of Pediatrics, vol. 96, no. 3, pp. 279–288, 2020.
View at: Publisher Site | Google Scholar
J. F. Ransom, I. N. King, V. Garg, and D. Srivastava, “A rare human sequence variant reveals myocardin autoinhibition,” The Journal of Biological Chemistry, vol. 283, no. 51, pp. 35845–35852, 2008.
View at: Publisher Site | Google Scholar
N. S. Diab, S. Barish, W. Dong et al., “Molecular genetics and complex inheritance of congenital heart disease,” Genes, vol. 12, no. 7, p. 1020, 2021.
View at: Publisher Site | Google Scholar
J. Yasuhara and V. Garg, “Genetics of congenital heart disease: a narrative review of recent advances and clinical implications,” Translational Pediatrics, vol. 10, no. 9, pp. 2366–2386, 2021.
View at: Publisher Site | Google Scholar
S. Maran, S. A. Faten, S. H. Lim et al., “Screening of 22q11.2DS using multiplex ligation-dependent probe amplification as an alternative diagnostic method,” BioMed Research International, vol. 2020, Article ID 6945730, 6 pages, 2020.
View at: Publisher Site | Google Scholar
S. S. Wang, T. M. Wang, X. H. Qiao et al., “KLF13 loss-of-function variation contributes to familial congenital heart defects,” European Review for Medical and Pharmacological Sciences, vol. 24, no. 21, pp. 11273–11285, 2020.
View at: Publisher Site | Google Scholar
X. F. Huang, L. Sun, C. Zhang et al., “Whole-exome sequencing reveals a rare missense variant in SLC16A9 in a pedigree with early-onset gout,” BioMed Research International, vol. 2020, Article ID 4321419, 6 pages, 2020.
View at: Publisher Site | Google Scholar
Y. Dong, R. Du, L. L. Fan et al., “Whole-exome sequencing identifies a novel TRPM4 mutation in a Chinese family with atrioventricular block,” BioMed Research International, vol. 2021, Article ID 9247541, 6 pages, 2021.
View at: Publisher Site | Google Scholar
U. Mahmood, S. A. Bukhari, M. Ali, Z. M. Ahmed, and S. Riazuddin, “Identification of hearing loss-associated variants of PTPRQ, MYO15A, and SERPINB6 in Pakistani families,” BioMed Research International, vol. 2021, Article ID 5584788, 6 pages, 2021.
View at: Publisher Site | Google Scholar
Z. X. Wang, Y. H. Liu, Y. Dong, Y. L. Li, T. Y. Tang, and L. L. Fan, “Whole-exome sequencing identified a novel homozygous frameshift mutation of HPS3 in a consanguineous family with hermansky-pudlak syndrome,” BioMed Research International, vol. 2021, Article ID 4535349, 7 pages, 2021.
View at: Publisher Site | Google Scholar
C. L. Lien, J. McAnally, J. A. Richardson, and E. N. Olson, “Cardiac-specific activity of an Nkx2 -5 enhancer requires an evolutionarily conserved Smad binding site,” Developmental Biology, vol. 244, no. 2, pp. 257–266, 2002.
View at: Publisher Site | Google Scholar
R. M. Di, C. X. Yang, C. M. Zhao et al., “Identification and functional characterization of KLF5 as a novel disease gene responsible for familial dilated cardiomyopathy,” European Journal of Medical Genetics, vol. 63, no. 4, article 103827, 2020.
View at: Publisher Site | Google Scholar
E. P. Kirk, M. Sunde, M. W. Costa et al., “Mutations in cardiac T-box factor gene TBX20 are associated with diverse cardiac pathologies, including defects of septation and valvulogenesis and cardiomyopathy,” American Journal of Human Genetics, vol. 81, no. 2, pp. 280–291, 2007.
View at: Publisher Site | Google Scholar
J. J. Schott, D. W. Benson, C. T. Basson et al., “Congenital heart disease caused by mutations in the transcription factor NKX2-5,” Science, vol. 281, no. 5373, pp. 108–111, 1998.
View at: Publisher Site | Google Scholar
M. S. Parmacek, “Myocardin-related transcription factors,” Circulation Research, vol. 100, no. 5, pp. 633–644, 2007.
View at: Publisher Site | Google Scholar
J. Huang, J. Elicker, N. Bowens et al., “Myocardin regulates BMP10 expression and is required for heart development,” The Journal of Clinical Investigation, vol. 122, no. 10, pp. 3678–3691, 2012.
View at: Publisher Site | Google Scholar
A. T. Mikhailov and M. Torrado, “In search of novel targets for heart disease: myocardin and myocardin-related transcriptional cofactors,” Biochemistry Research International, vol. 2012, Article ID 973723, 11 pages, 2012.
View at: Publisher Site | Google Scholar
P. A. Hoodless, T. Haerry, S. Abdollah et al., “MADR1, a MAD-related protein that functions in BMP2 signaling pathways,” Cell, vol. 85, no. 4, pp. 489–500, 1996.
View at: Publisher Site | Google Scholar
F. Liu, A. Hata, J. C. Baker, J. Doody, J. Carcamo, and R. M. Harland, “A human Mad protein acting as a BMP-regulated transcriptional activator,” Nature, vol. 381, no. 6583, pp. 620–623, 1996.
View at: Publisher Site | Google Scholar
L. Attisano and S. T. Lee-Hoeflich, “The Smads,” Genome Biology, vol. 2, no. 8, 2001.
View at: Publisher Site | Google Scholar
T. E. Callis, D. Cao, and D. Z. Wang, “Bone morphogenetic protein signaling modulates myocardin transactivation of cardiac genes,” Circulation Research, vol. 97, no. 10, pp. 992–1000, 2005.
View at: Publisher Site | Google Scholar
R. Singh, T. Horsthuis, H. F. Farin et al., “Tbx20 interacts with smads to confineTbx2expression to the atrioventricular canal,” Circulation Research, vol. 105, no. 5, pp. 442–452, 2009.
View at: Publisher Site | Google Scholar
E. M. Mandel, E. Kaltenbrun, T. E. Callis et al., “The BMP pathway acts to directly regulateTbx20in the developing heart,” Development, vol. 137, no. 11, pp. 1919–1929, 2010.
View at: Publisher Site | Google Scholar
J. T. Granados-Riveron, T. K. Ghosh, M. Pope et al., “α-Cardiac myosin heavy chain (MYH6) mutations affecting myofibril formation are associated with congenital heart defects,” Human Molecular Genetics, vol. 19, no. 20, pp. 4007–4016, 2010.
View at: Publisher Site | Google Scholar
T. Bjornsson, R. B. Thorolfsdottir, G. Sveinbjornsson et al., “A rare missense mutation in MYH6 associates with non-syndromic coarctation of the aorta,” European Heart Journal, vol. 39, no. 34, pp. 3243–3249, 2018.
View at: Publisher Site | Google Scholar
Y. Xia, S. Chen, Y. Yang et al., “Novel mutation in MYH6 in 2 unrelated Chinese Han families with familial atrial septal defect,” Circulation Genomic and Precision Medicine, vol. 12, no. 11, article e002732, 2019.
View at: Publisher Site | Google Scholar
S. C. Greenway, R. McLeod, S. Hume et al., “Exome sequencing identifies a novel variant in ACTC1 associated with familial atrial septal defect,” Canadian Journal of Cardiology, vol. 30, no. 2, pp. 181–187, 2014.
View at: Publisher Site | Google Scholar
O. W. Prall, M. K. Menon, M. J. Solloway et al., “An Nkx2-5/Bmp2/Smad1 negative feedback loop controls heart progenitor specification and proliferation,” Cell, vol. 128, no. 5, pp. 947–959, 2007.
View at: Publisher Site | Google Scholar
K. D. Tremblay, N. R. Dunn, and E. J. Robertson, “Mouse embryos lacking Smad1 signals display defects in extra-embryonic tissues and germ cell formation,” Development, vol. 128, no. 18, pp. 3609–3621, 2001.
View at: Publisher Site | Google Scholar
S. J. Arnold, S. Maretto, A. Islam, E. K. Bikoff, and E. J. Robertson, “Dose-dependent Smad1 , Smad5 and Smad8 signaling in the early mouse embryo,” Developmental Biology, vol. 296, no. 1, pp. 104–118, 2006.
View at: Publisher Site | Google Scholar
C. Han, K. H. Hong, Y. H. Kim et al., “SMAD1 deficiency in either endothelial or smooth muscle cells can predispose mice to pulmonary hypertension,” Hypertension, vol. 61, no. 5, pp. 1044–1052, 2013.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2022 Zhi Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

420

Downloads

866

Citations